Evidence map›Paper›PMID 38828674›Full record

ArticleHistopathology2024

Proposal for an optimised definition of adverse pathology (unfavourable histology) that predicts metastatic risk in prostatic adenocarcinoma independent of grade group and pathological stage.

Jane K Nguyen, Lara R Harik, Eric A Klein, Jianbo Li, Dillon Corrigan, Shiguang Liu, Emily Chan, Sarah Hawley, Heidi Auman, Lisa F Newcomb and 13 more

Abstract read
In one paragraph

Article in Histopathology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Current grading of prostate cancer.Pathologie (Heidelberg, Germany) · 2025
    Review
  8. Article
  9. [Current grading of prostate cancer. German version].Pathologie (Heidelberg, Germany) · 2025
    Review
  10. Article
  11. Is uptake of AS in low-risk prostate cancer in Ontario linked to guideline publication?Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2025
    Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Jane K NguyenRobert J. Tomsich Institute of Pathology and Laboratory Medicine, Cleveland Clinic, Cleveland, OH, USA.
Lara R HarikDepartment of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, USA.
Eric A KleinGlickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA.
Jianbo LiDepartment of Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
Dillon CorriganDepartment of Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
Shiguang LiuDepartment of Pathology, University of Florida Health, Jacksonville, FL, USA.
Emily ChanDepartment of Pathology, University of California San Francisco, San Francisco, CA, USA.
Sarah HawleyCanary Foundation, Palo Alto, CA, USA.
Heidi AumanCanary Foundation, Palo Alto, CA, USA.
Lisa F NewcombFred Hutchinson Cancer Center, Seattle, WA, USA.
Peter R CarrollDepartment of Urology, University of California San Francisco, San Francisco, CA, USA.
Matthew R CooperbergDepartment of Urology, University of California San Francisco, San Francisco, CA, USA.
Christopher P FilsonDepartment of Urology, Emory University School of Medicine, Atlanta, GA, USA.
Jeff P SimkoDepartment of Pathology, University of California San Francisco, San Francisco, CA, USA.
Peter S NelsonFred Hutchinson Cancer Center, Seattle, WA, USA.
Maria S TretiakovaDepartment of Laboratory Medicine and Pathology, University of Washington Medical Center, Seattle, WA, USA.ORCID https://orcid.org/0000-0002-0819-9638
Dean TroyerDepartment of Pathology, Eastern Virginia Medical School, Norfolk, VA, USA.
Lawrence D TrueDepartment of Laboratory Medicine and Pathology, University of Washington Medical Center, Seattle, WA, USA.
Funda Vakar-LopezDepartment of Laboratory Medicine and Pathology, University of Washington Medical Center, Seattle, WA, USA.
Christopher J WeightGlickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA.
Daniel W LinFred Hutchinson Cancer Center, Seattle, WA, USA.
James D BrooksDepartment of Urology, Stanford University Medical Center, Stanford, CA, USA.
Jesse K McKenneyRobert J. Tomsich Institute of Pathology and Laboratory Medicine, Cleveland Clinic, Cleveland, OH, USA.ORCID https://orcid.org/0000-0003-0851-1465

Funding

TRANSCRIPTOME AND PROTEOME STRATIFICATION OF PROSTATE ADENOCARCINOMA PHENOTYPESP50CA097186 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI PETER S NELSON · 2002 to 2026
$58.1M
Prostate cancer Active Surveillance Study (PASS) Cohort: Infrastructure Support for Cancer ResearchU01CA224255 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI LIN, DANIEL W. · 2019 to 2023
$6.7M
Canary FoundationNational Institute of Health UO1 CA22425NCI NIH HHS P50 CA097186NCI NIH HHS U01 CA224255PNW Prostate Cancer SPORE CA097186Roswell Country Club Prostate Cancer Research AwardWinship Cancer Institute of Emory University
6 · The paper itself

Abstract

aimsHistological grading of prostate cancer is a powerful prognostic tool, but current criteria for grade assignment are not fully optimised. Our goal was to develop and test a simplified histological grading model, based heavily on large cribriform/intraductal carcinoma, with optimised sensitivity for predicting metastatic potential. METHODS AND

resultsTwo separate non-overlapping cohorts were identified: a 419-patient post-radical prostatectomy cohort with long term clinical follow-up and a 209-patient post-radical prostatectomy cohort in which all patients had pathologically confirmed metastatic disease. All prostatectomies were re-reviewed for high-risk histological patterns of carcinoma termed 'unfavourable histology'. Unfavourable histology is defined by any classic Gleason pattern 5 component, any large cribriform morphology (> 0.25 mm) or intraductal carcinoma, complex intraluminal papillary architecture, grade 3 stromogenic carcinoma and complex anastomosing cord-like growth. For the outcome cohort, Kaplan-Meier analysis compared biochemical recurrence, metastasis and death between subjects with favourable and unfavourable histology, stratified by pathological stage and grade group. Multivariable Cox proportional hazards models evaluated adding unfavourable histology to the Memorial Sloan Kettering Cancer Center (MSKCC) post-prostatectomy nomogram and stratification by percentage of unfavourable histology. At 15 years unfavourable histology predicted biochemical recurrence, with sensitivity of 93% and specificity of 88%, metastatic disease at 100 and 48% and death at 100 and 46%. Grade group 2 prostate cancers with unfavourable histology were associated with metastasis independent of pathological stage, while those without had no risk. Histological models for prediction of metastasis based on only large cribriform/intraductal carcinoma or increasing diameter of cribriform size improved specificity, but with lower sensitivity. Multivariable Cox proportional hazards models demonstrated that unfavourable histology significantly improved discriminatory power of the MSKCC post-prostatectomy nomogram for biochemical failure (likelihood ratio test P < 0.001). In the retrospective review of a separate RP cohort in which all patients had confirmed metastatic disease, none had unequivocal favourable histology.

conclusionsUnfavourable histology at radical prostatectomy is associated with metastatic risk, predicted adverse outcomes better than current grading and staging systems and improved the MSKCC post-prostatectomy nomogram. Most importantly, unfavourable histology stratified grade group 2 prostate cancers into those with and without metastatic potential, independent of stage. While unfavourable histology is driven predominantly by large cribriform/intraductal carcinoma, the recognition and inclusion of other specific architectural patterns add to the sensitivity for predicting metastatic disease. Moreover, a simplified dichotomous model improves communication and could increase implementation.

Indexed as

AdenocarcinomaNeoplasm GradingProstatectomyProstatic NeoplasmsAgedCohort StudiesHumansKaplan-Meier EstimateMaleMiddle AgedNeoplasm MetastasisNeoplasm StagingNomogramsPrognosisProportional Hazards ModelsadenocarcinomacribriformGleasongradeprostate

Identifiers

PMID38828674
PMCPMC11365761

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.